How Can Targeting Protein Degradation Be a Therapeutic Strategy?
Targeting protein degradation pathways offers a promising approach to cancer therapy. By manipulating these pathways, it is possible to selectively induce the degradation of oncogenic proteins or stabilize tumor suppressors. For example, proteasome inhibitors, such as bortezomib, have been successfully used in the treatment of multiple myeloma by disrupting the degradation of pro-apoptotic factors, thereby inducing cancer cell death.
